The Manila Times

Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

Funding to support the execution of a Phase 2 proof-of-concept trial of HER-096 in Parkinson’s disease, following completion of study preparationsEspoo, Finland, 19 2026: Herantis Pharma Plc ...

Palisades Therapeutics Receives FDA Clearance to PROCEED with Phase 2a PTSD Trial of PT150 in U.S. Veterans

DoD-Funded Study Accelerates Novel PTSD Mechanism into Trials; Proven Alcohol Safety Profile De-Risks Program for ...

Tark Thermal Solutions’ EFC2400 Natural Refrigerant Chiller Aligns with Latest EU F‑Gas Regulation

The EFC2400 leverages nearly a decade of our experience in customer‑specific natural refrigerant systems and packages ...

Herantis Pharma Oyj: Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096

EET Inside information: Herantis Pharma selected for Horizon 2025 grant of EUR 8.0 million for Phase 2 trial of HER-096 Funding to support ...

Evommune's EVO301 Phase 2a Data Drives 70% Stock Surge

Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...
The Manila Times

MerryLife Biomedical Reports Positive Phase 1 Results and Plans for Global Phase 2 Trial for TML-6, an Oral Multi-Targeted Investigational Therapy for Alzheimer's Dise…

MerryLife Biomedical Inc., a clinical-stage biotechnology company focused on neurodegenerative diseases, today announced ...

Nektar Therapeutics: Unique MOA Translates To Stellar AD Maintenance Data, Strong Buy

Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. Click ...

Equillium Conference: EQ504 Targets Ulcerative Colitis Ahead of Mid-Year Phase 1 Start

Executives from Equillium (NASDAQ:EQ) outlined the scientific rationale and near-term development plans for its lead program, EQ504, during a recent fireside chat focused on immunology and ...

CAR‑T Therapy Expands Beyond Cancer: Creative Biolabs Advances Solid Tumor and Non‑Oncology Engineering Strategies

Creative Biolabs is accelerating CAR‑T innovation, driving breakthroughs in solid tumor targeting. SHIRLEY, NY, UNITED ...

INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease

Agency Feedback Provides Regulatory Clarity on Enrichment Strategy and Confirms CDR-SB as Sole Primary Endpoint for Registrational ...
Cantech Letter

Devonian Reports Human Liver-on-a-Chip Data Demonstrating Disease-Relevant Modulation of MASH by Thykamine™, with Dose-Dependent Anti-Fibrotic and Anti-Inflammatory Effects

Devonian Health Group Inc. (“Devonian” or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study ...